Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
about
Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is identical to SART2Cancer immunotherapy: moving beyond current vaccinesProstate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.Clinical applications of a peptide-based vaccine for glioblastoma.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma.Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer.Trial watch: Peptide vaccines in cancer therapyPersonalized peptide vaccines: a new therapeutic modality for cancer.A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patientsBiological functions of iduronic acid in chondroitin/dermatan sulfate.Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.DNA vaccination: using the patient's immune system to overcome cancerProstate cancer vaccines in clinical trials.Next-generation peptide vaccines for advanced cancer.Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.Immunotherapy in prostate cancer: challenges and opportunities.Clinical development of immunotherapy for prostate cancer.Prospect and progress of personalized peptide vaccinations for advanced cancers.Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients.Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients.Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.Personalized peptide vaccines and their relation to other therapies in urological cancer.Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas.A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction.Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b(+) HLA-A24(+) patients.
P2860
Q24306073-FCB0D480-0C3E-48C1-B8CD-C1CFBBF9F62FQ24548229-61D569B3-A8B2-49E0-B590-D3A43357691FQ33606027-0FE4831D-913B-43CB-B575-64BD15FBBA62Q33668575-C0FB0BF4-76F4-432C-BC71-0BD0DDA403FFQ33872776-4E9E5291-2584-4C47-A0F7-F44DD32A4CE9Q34111719-D7898EDE-1D93-4396-975C-FF1615664CAEQ34577158-137E4AF0-3F88-44D3-AF43-5A7A6CFBA4D6Q35076925-16D6FA36-A752-4FB8-A8D8-6FDB6A958204Q35826392-0EA2BECE-BA31-4009-991B-1C785C69A75BQ35894756-1DF5DA49-D83F-4D78-BCF9-30DFB8E0EF4CQ36230559-4C075770-81A0-4E21-84B2-03C99B191832Q36476100-2C6E6F32-F1CC-495C-9FE6-6CF2772BA4F0Q36597682-528ED4B3-9E04-4B20-98A7-04E1B78690FCQ36626087-8601A11B-955D-4277-9792-6811320C7694Q36694874-74C30599-582A-4516-B6CE-453DB2943301Q37029047-A6C19F10-30A0-4C98-A679-66B8532C88E7Q37192915-CFAE7E5A-D0E7-4A55-99B4-E46475B9EDE8Q37825422-B8CE9431-CFEA-44ED-AB37-93038A398875Q38036690-A0592758-F77B-42F7-8E71-A654FBB042A5Q38056246-171C9611-81DC-44D6-8A22-6C35BA6C224DQ38063819-073DE9E2-B1D1-45DA-80B8-A2D05751463DQ38661079-F6B73E46-D0A3-48AE-BA22-73757AEDCF38Q38668561-6C926B58-7ABC-423E-9155-EB9293500115Q38758988-660DF7FA-96B9-4E20-8E8D-FCCC27436DF0Q38798383-669ACE32-B508-4F49-9AAD-A759F34843C3Q38800120-A3CE66DE-ABB0-4B56-9299-18C78CC9DCB1Q39162824-C7A72C3B-212B-48EB-B2C2-097A3491EFE8Q39340541-A04BB1C1-2BD2-4698-8F37-987B740820B4Q39914585-B923B604-63E8-4669-83C5-F58B9600F6EEQ40383827-4C5BCB40-3903-4DF9-AF1F-8B027C01DF49Q41002117-45D76A46-C562-453D-9252-A54D05A2EB1BQ42986524-F9D37454-2BBC-411A-9428-915DE0CCDB24Q44424699-7A2A95B1-58BB-4D60-8326-81233DA8F686Q44521320-9D3941E6-3A49-4D2D-86DA-410C91AE8C9B
P2860
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Induction of cellular and humo ...... tients by peptide vaccination.
@en
Induction of cellular and humo ...... tients by peptide vaccination.
@nl
type
label
Induction of cellular and humo ...... tients by peptide vaccination.
@en
Induction of cellular and humo ...... tients by peptide vaccination.
@nl
prefLabel
Induction of cellular and humo ...... tients by peptide vaccination.
@en
Induction of cellular and humo ...... tients by peptide vaccination.
@nl
P2093
P356
P1433
P1476
Induction of cellular and humo ...... tients by peptide vaccination.
@en
P2093
Akira Yamada
Katsurou Tomiyasu
Kazuhiko Kobayashi
Kyogo Itoh
Masanori Noguchi
Norie Suetsugu
Shigetaka Suekane
Shinshi Noda
P356
10.1002/PROS.10276
P577
2003-09-01T00:00:00Z